

Press release 2014-07-22

WntResearch stocks

Nils Brünner, CEO and Tommy Andersson, CSO, WntResearch have of pure personal reasons sold a small part of their stocks in WntResearch. Both still have a significant amount of stocks in WntResearch and do not know of any negative information on the ongoing clinical phase 1 study which is running according to the plans and with no observations of dose limiting toxicities . We all have a strong believe in WntResearch and its future development.

För ytterligare information vänligen kontakta:

Nils Brünner, VD

E-post: nbr@wntresearch.com

Telefon: + 45 2614 4708

Om WntResearch

WntResearch AB är ett publikt bolag noterat på AktieTorget. WntResearch utvecklar läkemedel för behandling vid metastaserande cancer. WntResearch har en läkemedelskandidat i klinisk fas 1 – Foxy-5 – samt ett utvecklingsprogram – Box-5. Bolaget fokuserar på klinisk utveckling av Foxy-5.